Using drug sensitivity profiling of primary leukemia cells and CRISPR/Cas9 RUNX1 gene-edited CML cell lines, we identified novel effective targeted therapies and CD19-CAR T cells as a promising immunotherapeutic option. This evidence concerns the gene RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive.